We focus on Asian cohorts and diseases to build up an epigenomic database that serves as a platform for novel drug and biomarker discoveries. We develop proprietary epigenomics-based predictive models across cancer types to deliver clinically actionable insights that complement existing genomic information.
More than 10 years of medtech experience across public/private and different functions; proven experience in growing teams from scratch till beyond Series B
Prolific thought leader in epigenomics and cancer biology; developed and optimised subgroup specific treatments for gastric cancer patients based on molecular subtypes
Distinguished expert in medical (epi)genetics for Asian-prevalent cancers and drug discovery
Company incorporation •
Raised Angel round •
Awarded Illumina Bay Area Accelerator Award previously •
• Awarded Enterprise Singapore Startup SG POC Grant
Launched Signomax™ service with ChIP-Seq •
Awarded Singapore Biodesign Prototyping Grant 2022 •
• Expanded Signomax™ service to include RNA-Seq
Awarded Enterprise Singapore Startup SG POV Grant •
• Launched EPI-CALL™ RUO service
• Awarded Singapore Biodesign Prototyping Grant 2023
Raised SEED round •
Awarded A*STAR T-Up Award 2023 •
• Launch of EPI-CALL™ LDT service
• Company incorporation
• Raised Angel round
• Awarded Illumina Bay Area Accelerator Award previously
• Awarded Enterprise Singapore Startup SG POC Grant
• Launched Signomax™ service with ChIP-Seq
• Awarded Singapore Biodesign Prototyping Grant 2022
• Expanded Signomax™ service to include RNA-Seq
• Awarded Enterprise Singapore Startup SG POV Grant
• Launched EPI-CALL™ RUO service
•Awarded Singapore Biodesign Prototyping Grant 2023
• Raised SEED round
• Awarded A*STAR T-Up Award 2023
•Launch of EPI-CALL™ LDT service
Interested in working with us? Drop us a note below and we’ll get back to you as soon as we can.
enquiry@auristone.com
LaunchPad @ one-north
73 Ayer Rajah Crescent, #02-19 Singapore 139952
